Market: NMS |
Currency: USD
Address: 2222 Ponce de Leon Boulevard
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
📈 Relmada Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$12.80
-
Upside/Downside from Analyst Target:
228.21%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-05-12
-
EPS Estimate:
-0.19
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Relmada Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-05-11 (estimated upcoming) | - |
| 2026-03-19 | -0.29 |
| 2025-11-13 | -0.3 |
| 2025-05-12 | -0.58 |
| 2025-03-27 | -0.62 |
| 2024-11-07 | -0.72 |
| 2024-08-07 | -0.59 |
| 2024-05-08 | -0.72 |
| 2024-03-19 | -0.84 |
| 2023-11-08 | -0.73 |
| 2023-08-08 | -0.84 |
| 2023-05-11 | -0.87 |
| 2023-03-23 | -1.26 |
| 2022-11-10 | -1.26 |
| 2022-08-11 | -1.08 |
| 2022-05-05 | -1.4 |
| 2022-03-23 | -1.06 |
| 2021-11-11 | -2.42 |
| 2021-08-10 | -1.53 |
| 2021-05-12 | -1.33 |
| 2021-03-23 | -1.28 |
| 2020-11-12 | -1.05 |
| 2020-08-12 | -0.81 |
| 2020-05-15 | -0.66 |
| 2020-03-26 | -0.39 |
📰 Related News & Research
🔍 View more Reports
